Histogenics Corporation (HSGX) Releases Earnings Results, Beats Expectations By $0.07 EPS
Histogenics Corporation (NASDAQ:HSGX) released its earnings results on Thursday. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.07, Bloomberg Earnings reports.
Histogenics Corporation (HSGX) traded down $0.01 during midday trading on Friday, hitting $2.02. 53,445 shares of the stock were exchanged, compared to its average volume of 140,652. Histogenics Corporation has a 1-year low of $1.45 and a 1-year high of $2.41.
HSGX has been the subject of a number of research analyst reports. Zacks Investment Research lowered Histogenics Corporation from a “buy” rating to a “hold” rating and set a $2.00 target price for the company. in a report on Friday, September 1st. Canaccord Genuity restated a “buy” rating and issued a $4.00 target price on shares of Histogenics Corporation in a report on Friday, August 11th. HC Wainwright restated a “buy” rating and issued a $3.50 target price on shares of Histogenics Corporation in a report on Thursday, November 2nd. Finally, ValuEngine lowered Histogenics Corporation from a “sell” rating to a “strong sell” rating in a report on Monday, August 14th.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/histogenics-corporation-hsgx-releases-earnings-results-beats-expectations-by-0-07-eps/1694136.html.
Histogenics Corporation Company Profile
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Receive News & Ratings for Histogenics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.